MX2022004522A - Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas. - Google Patents
Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas.Info
- Publication number
- MX2022004522A MX2022004522A MX2022004522A MX2022004522A MX2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A MX 2022004522 A MX2022004522 A MX 2022004522A
- Authority
- MX
- Mexico
- Prior art keywords
- physiologically active
- active substances
- highly lipophilic
- controlled release
- release formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19203549.1A EP3808336A1 (de) | 2019-10-16 | 2019-10-16 | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
| PCT/EP2020/079244 WO2021074399A1 (de) | 2019-10-16 | 2020-10-16 | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004522A true MX2022004522A (es) | 2022-09-19 |
Family
ID=68281165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004522A MX2022004522A (es) | 2019-10-16 | 2020-10-16 | Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240148758A1 (https=) |
| EP (2) | EP3808336A1 (https=) |
| JP (2) | JP7850068B2 (https=) |
| CN (1) | CN114929197A (https=) |
| AU (1) | AU2020366134B2 (https=) |
| BR (1) | BR112022006678A2 (https=) |
| CA (1) | CA3157693A1 (https=) |
| IL (1) | IL292019A (https=) |
| MX (1) | MX2022004522A (https=) |
| WO (1) | WO2021074399A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| SK287111B6 (sk) * | 1998-08-27 | 2009-12-07 | Pharmacia & Upjohn Ab | Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním |
| DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| WO2008021394A2 (en) * | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
| WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| US20130338220A1 (en) * | 2010-10-05 | 2013-12-19 | Mark Tepper | Compositions, dosages, and methods of using tetrahydrocannabinol derivatives |
| AU2014340709B2 (en) | 2013-10-29 | 2019-07-04 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
| WO2018035030A1 (en) | 2016-08-15 | 2018-02-22 | Corr-Jensen Inc. | Time release fat-soluble actives |
| EP3808341A1 (de) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
-
2019
- 2019-10-16 EP EP19203549.1A patent/EP3808336A1/de not_active Withdrawn
-
2020
- 2020-10-16 WO PCT/EP2020/079244 patent/WO2021074399A1/de not_active Ceased
- 2020-10-16 CN CN202080072481.0A patent/CN114929197A/zh active Pending
- 2020-10-16 MX MX2022004522A patent/MX2022004522A/es unknown
- 2020-10-16 JP JP2022521680A patent/JP7850068B2/ja active Active
- 2020-10-16 IL IL292019A patent/IL292019A/en unknown
- 2020-10-16 US US17/769,398 patent/US20240148758A1/en active Pending
- 2020-10-16 AU AU2020366134A patent/AU2020366134B2/en active Active
- 2020-10-16 BR BR112022006678A patent/BR112022006678A2/pt unknown
- 2020-10-16 CA CA3157693A patent/CA3157693A1/en active Pending
- 2020-10-16 EP EP20800799.7A patent/EP4045007A1/de active Pending
-
2025
- 2025-12-24 JP JP2025279962A patent/JP2026034780A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022553652A (ja) | 2022-12-26 |
| CN114929197A (zh) | 2022-08-19 |
| JP2026034780A (ja) | 2026-02-27 |
| AU2020366134A1 (en) | 2022-05-26 |
| IL292019A (en) | 2022-06-01 |
| CA3157693A1 (en) | 2021-04-22 |
| US20240148758A1 (en) | 2024-05-09 |
| JP7850068B2 (ja) | 2026-04-22 |
| EP4045007A1 (de) | 2022-08-24 |
| EP3808336A1 (de) | 2021-04-21 |
| AU2020366134B2 (en) | 2026-04-23 |
| WO2021074399A1 (de) | 2021-04-22 |
| BR112022006678A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38602A (es) | Compuestos tricíclicos condensados | |
| CO2022002842A2 (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| WO2020016659A3 (en) | Multiparticulate formulations of cannabinoids | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| ECSP18082774A (es) | Derivados aromáticos de sulfonamida | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| PE20201163A1 (es) | Composiciones y tratamientos para el trastorno del sueno | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| AR086409A1 (es) | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| CL2018000712A1 (es) | Adyuvantes mejorados para productos agroquímicos | |
| CL2019003619A1 (es) | Preparación sólida para administración oral. | |
| MX2022006903A (es) | Productos orales con irritacion reducida. | |
| CL2020002101A1 (es) | Formulaciones de liberación sostenida de ácido bempedoico. | |
| MX2021012904A (es) | Moduladores de la via de respuesta al estres integrada. | |
| CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
| PY1929301A (es) | Formulación sólida de mezclas insecticidas.- | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| CO2022008308A2 (es) | Tieniloxazolonas y análogos | |
| CO2019000604A2 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| MX2022004523A (es) | Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas. | |
| MX2023011701A (es) | Composicion farmaceutica para liberacion controlada de treprostinil. | |
| BR112016001742A2 (pt) | composições fungicidas e seu uso |